Phillip Mertz
Director/Board Member chez ALPHA COGNITION INC.
Fortune : 728 377 $ au 31/03/2024
Postes actifs de Phillip Mertz
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALPHA COGNITION INC. | Director/Board Member | 22/03/2021 | - |
Historique de carrière de Phillip Mertz
Anciens postes connus de Phillip Mertz
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Alpha Cognition, Inc. /old/
 Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Director/Board Member | - | - |
Formation de Phillip Mertz
| Harvard University | Undergraduate Degree |
Statistiques
Internationale
| Canada | 3 |
| Etats-Unis | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALPHA COGNITION INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alpha Cognition, Inc. /old/
Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Health Technology |
- Bourse
- Insiders
- Phillip Mertz
- Expérience
